HTA - 16/31/13

A phase 3 trial of Rivastigmine to prevent falls in Parkinson's Disease

Project title: A phase 3 trial of Rivastigmine to prevent falls in Parkinson's Disease

Call to action: 16/31 16/31 HTA CET, HTA EoI to Full Form, closing 10 August 2016

Research type: Primary Research

Chief investigator: Dr Emily Henderson

Contractor: Royal United Hospital Bath NHS Foundation Trust

Cost: £2,429,152.72

Co-investigators: Dr Alan Whone, Mrs Diana Steeds, Professor Chris Metcalfe, Professor William Hollingworth, Professor Yoav Ben-Shlomo.

Started: April 2018 | Status: Research in progress

ISRCTN: 41639809

Links to project documentation

The links and documents below are related to this research and are added as and when they are produced over the life of the project. The information is provided by the researchers and some may have undergone varying editorial, production and publication models, which differ to NIHR Journals Library reports. Links are to both internal (NIHR) and external websites – the NIHR is not responsible for the content of external websites.